TapImmune Inc, a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has signed a license agreement with Crucell NV.

Under the license TapImmune may use the proprietary PER.C6 cells in its development programmes. The PER.C6 cell line is ideally suited for the development and large-scale manufacturing of a multitude of biopharmaceuticals. In the use of recombinant vaccines using adenoviral vectors, PER.C6 cells do not generate replication competent adenoviruses, making it the state-of-the-art platform for the large-scale production of adenoviral vectors for clinical applications.

The PER.C6 cell line is the best documented cell line for vaccine development to date. Its extensive Biologics Master File at the US FDA can be cross-referenced by licensees, resulting in simplification and acceleration of the IND filing and approval process.

The partnership between TapImmune and Crucell is important for the production of TapImmune's vaccine products. Under the terms of this agreement, Crucell has the rights to negotiate a license for TapImmune's TAP technologies for infectious disease indications.

TapImmune is a biotechnology company specializing in the development of innovative cell based immunotherapeutics and vaccines in the areas of oncology and infectious disease.